Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral acyclovir for infectious mononucleosis in hospitalized children
IRCT20201201049554N1Phase 3Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of aciclovir in infectious mononucleosis (IM) (2 arms), sponsored by Golestan University of Medical Sciences. Primary endpoints: Reduction in treatment duration and Reduction in disease severity. Started Mar 2021; status: completed.
02
Drugs
aciclovir
03
Conditions
infectious mononucleosis (IM)
Beyond the preview
Go deeper on IRCT20201201049554N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201201049554N1.